CD274 and urothelial carcinoma: Other reports in this supplement present similar findings in NSCLC (PD-L1 TPS ≥ 50%), urothelial carcinoma, renal cell carcinoma and head and neck squamous cell carcinoma (see accompanying articles, this issue).